BerGenBio ASA
BRRGF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $848 | $354 | $389 | $774 |
| % Growth | 139.5% | -9% | -49.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $848 | $354 | $389 | $774 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $87,691 | $107,786 | $8,340 | $12,744 |
| G&A Expenses | $0 | $0 | $0 | $12,744 |
| SG&A Expenses | $0 | $0 | $105,057 | $12,744 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $64,391 | $84,387 | $297,684 | $289,748 |
| Operating Expenses | $152,082 | $192,173 | $306,024 | $315,236 |
| Operating Income | -$151,234 | -$191,819 | -$305,635 | -$314,464 |
| % Margin | -17,834.2% | -54,186.2% | -78,569.4% | -40,628.4% |
| Other Income/Exp. Net | $11,952 | $1,418 | $3,513 | $5,100 |
| Pre-Tax Income | -$139,282 | -$190,401 | -$302,122 | -$309,364 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$139,282 | -$190,401 | -$298,609 | -$309,417 |
| % Margin | -16,424.8% | -53,785.6% | -76,763.2% | -39,976.4% |
| EPS | -11.65 | -19.95 | -38.65 | -40.36 |
| % Growth | 41.6% | 48.4% | 4.2% | – |
| EPS Diluted | -11.65 | -19.95 | -38.65 | -40.36 |
| Weighted Avg Shares Out | 11,956 | 9,542 | 7,726 | 7,666 |
| Weighted Avg Shares Out Dil | 11,956 | 9,542 | 7,726 | 7,666 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16,653 | $3,055 | $2,949 | $3,130 |
| Interest Expense | $4,700 | $578 | $321 | $53 |
| Depreciation & Amortization | $456 | $223 | $883 | $1,312 |
| EBITDA | -$134,126 | -$189,600 | -$300,918 | -$307,999 |
| % Margin | -15,816.7% | -53,559.3% | -77,356.8% | -39,793.2% |